Top

Published in:

Open Access 01-03-2011 | Editorial

Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging

Authors: Christiaan Schiepers, Magnus Dahlbom

Published in: European Radiology | Issue 3/2011

Abstract

In the last decade, PET-only systems have been phased out and replaced with PET-CT systems. This merger of a functional and anatomical imaging modality turned out to be extremely useful in clinical practice. Currently, PET-CT is a major diagnostic tool in oncology. At the dawn of the merger of MRI and PET, another breakthrough in clinical imaging is expected. The combination of these imaging modalities is challenging, but has particular features such as imaging biological processes at the same time in specific body locations.

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed

Schiepers C, Hoh CK (1998) Positron emission tomography as a diagnostic tool in oncology. Eur Radiol 8:1481–1494CrossRefPubMed

Townsend DW, Cherry SR (2001) Combining anatomy and function: the path to true image fusion. Eur Radiol 11:1968–1974CrossRefPubMed

Pichler BJ, Kolb A, Nagele T et al (2010) PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 51:333–336CrossRefPubMed

Siegel BA, Dehdashti F (2005) Oncologic PET/CT: current status and controversies. Eur Radiol 15(Suppl 4):D127–132PubMed

Denecke T, Rau B, Hoffmann KT et al (2005) Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol 15:1658–1666CrossRefPubMed

Schmidt GP, Haug AR, Schoenberg SO et al (2006) Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 16:1216–1225CrossRefPubMed

Lakkaraju A, Patel CN, Bradley KM et al (2010) PET/CT in primary musculoskeletal tumours: a step forward. Eur Radiol 20:2959–2972CrossRefPubMed

Gambhir SS, Czernin J, Schwimmer J et al (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S–93SPubMed

10.

Dahlbom M, Hoffman EJ, Hoh CK et al (1992) Whole-body positron emission tomography. 1. Methods and performance characteristics. J Nucl Med 33:1191–1199PubMed

11.

Goerres GW, Burger C, Schwitter MW et al (2003) PET/CT of the abdomen: optimizing the patient breathing pattern. Eur Radiol 13:734–739CrossRefPubMed

12.

de Juan R, Seifert B, Berthold T et al (2004) Clinical evaluation of a breathing protocol for PET/CT. Eur Radiol 14:1118–1123CrossRefPubMed

13.

Kinahan PE, Hasegawa BH, Beyer T (2003) X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 33:166–179CrossRefPubMed

14.

Kamel EM, Burger C, Buck A et al (2003) Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol 13:724–728PubMed

15.

von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology 238:405–422CrossRef

16.

Blodgett TM, Meltzer CC, Townsend DW (2007) PET/CT: form and function. Radiology 242:360–385CrossRefPubMed

17.

Freudenberg LS, Rosenbaum SJ, Beyer T et al (2010) PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Thorac Surg Clin 20:25–30CrossRefPubMed

18.

Ell PJ (2006) The contribution of PET/CT to improved patient management. Br J Radiol 79:32–36CrossRefPubMed

19.

Blomqvist L, Torkzad MR (2003) Whole-body imaging with MRI or PET/CT: the future for single-modality imaging in oncology? JAMA 290:3248–3249CrossRefPubMed

20.

Patil VV, Wang ZJ, Sollitto RA et al (2009) 18F-FDG PET/CT of transitional cell carcinoma. AJR Am J Roentgenol 193:W497–504CrossRefPubMed

21.

Podoloff DA, Macapinlac HA (2007) PET and PET/CT in management of the lymphomas. Radiol Clin North Am 45:689–696, viiCrossRefPubMed

22.

Prakash P, Cronin CG, Blake MA (2010) Role of PET/CT in ovarian cancer. AJR Am J Roentgenol 194:W464–470CrossRefPubMed

23.

Wahl RL (2004) Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 45(Suppl 1):82S–95SPubMed

24.

Lardinois D, Weder W, Hany TF et al (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507CrossRefPubMed

25.

Goerres GW, Michel SC, Fehr MK et al (2003) Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 13:1635–1644CrossRefPubMed

26.

Fueger BJ, Weber WA, Quon A et al (2005) Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 7:369–376CrossRefPubMed

27.

Radan L, Ben-Haim S, Bar-Shalom R et al (2006) The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107:2545–2551CrossRefPubMed

28.

Veit-Haibach P, Antoch G, Beyer T et al (2007) FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 80:508–515CrossRefPubMed

29.

Kumar A, Kumar R, Seenu V et al (2009) The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 19:1347–1357CrossRefPubMed

30.

Schiepers C (2003) PET/CT in Colorectal Cancer. J Nucl Med 44:1804–1805PubMed

31.

Kinner S, Antoch G, Bockisch A et al (2007) Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging 32:606–612CrossRefPubMed

32.

Schmidt GP, Baur-Melnyk A, Haug A et al (2009) Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur Radiol 19:1366–1378CrossRefPubMed

33.

Schaefer O, Langer M (2007) Detection of recurrent rectal cancer with CT, MRI and PET/CT. Eur Radiol 17:2044–2054CrossRefPubMed

34.

Al-Ibraheem A, Buck A, Krause BJ et al (2009) Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer. J Oncol 2009:208725PubMed

35.

Hustinx R, Lucignani G (2010) PET/CT in head and neck cancer: an update. Eur J Nucl Med Mol Imaging 37:645–651CrossRefPubMed

36.

Yoon DY, Hwang HS, Chang SK et al (2009) CT, MR, US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol 19:634–642CrossRefPubMed

37.

Kitajima K, Murakami K, Yamasaki E et al (2008) Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 18:2040–2047CrossRefPubMed

38.

Grigsby PW (2008) The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging 8:146–155CrossRefPubMed

39.

Kidd EA, Siegel BA, Dehdashti F et al (2010) Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 28:2108–2113CrossRefPubMed

40.

Ng SH, Chan SC, Yen TC et al (2010) Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. Eur Radiol 20:2229–2240CrossRefPubMed

41.

Freudenberg LS, Frilling A, Kuhl H et al (2007) Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 17:3139–3147CrossRefPubMed

42.

Freudenberg LS, Antoch G, Jentzen W et al (2004) Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14:2092–2098CrossRefPubMed

43.

Aukema TS, Valdes Olmos RA, Wouters MW et al (2010) Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol 17:2773–2778CrossRefPubMed

44.

Schoder H, Larson SM, Yeung HW (2004) PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 45(Suppl 1):72S–81SPubMed

45.

Strobel K, Dummer R, Husarik DB et al (2007) High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 244:566–574CrossRefPubMed

46.

Allen-Auerbach M, de Vos S, Czernin J (2008) The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 46:199–211, viiCrossRefPubMed

47.

Hofman MS, Smeeton NC, Rankin SC et al (2009) Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med 50:1594–1597CrossRefPubMed

48.

Kasamon YL, Jones RJ, Wahl RL (2007) Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48(Suppl 1):19S–27SPubMed

49.

Kwee TC, Kwee RM (2009) Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 19:731–744CrossRefPubMed

50.

Rosenbaum SJ, Lind T, Antoch G et al (2006) False-positive FDG PET uptake—the role of PET/CT. Eur Radiol 16:1054–1065CrossRefPubMed

51.

Costelloe CM, Murphy WA Jr, Chasen BA (2009) Musculoskeletal pitfalls in 18F-FDG PET/CT: pictorial review. AJR Am J Roentgenol 193:WS1–WS13, Quiz S26–30CrossRefPubMed

52.

Adams MC, Turkington TG, Wilson JM et al (2010) A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 195:310–320CrossRefPubMed

53.

Schiepers C, Hoh CK, Nuyts J et al (2008) 1-11C-acetate kinetics of prostate cancer. J Nucl Med 49:206–215CrossRefPubMed

54.

Apostolova I, Wiemker R, Paulus T et al (2010) Combined correction of recovery effect and motion blur for SUV quantification of solitary pulmonary nodules in FDG PET/CT. Eur Radiol 20:1868–1877CrossRefPubMed

55.

Blake MA, Setty BN, Cronin CG et al (2010) Evaluation of the effects of oral water and low-density barium sulphate suspension on bowel appearance on FDG-PET/CT. Eur Radiol 20:157–164CrossRefPubMed

56.

de Geus-Oei LF, Vriens D, van Laarhoven HW et al (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50(Suppl 1):43S–54SCrossRefPubMed

57.

Jarritt PH, Carson KJ, Hounsell AR et al (2006) The role of PET/CT scanning in radiotherapy planning. Br J Radiol 79 Spec No 1:S27–35

58.

Ford EC, Herman J, Yorke E et al (2009) 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 50:1655–1665CrossRefPubMed

59.

Messa C, Di Muzio N, Picchio M et al (2006) PET/CT and radiotherapy. Q J Nucl Med Mol Imaging 50:4–14PubMed

60.

Minn H, Suilamo S, Seppala J (2010) Impact of PET/CT on planning of radiotherapy in head and neck cancer. Q J Nucl Med Mol Imaging 54:521–532PubMed

61.

Budinger TF (1983) Time-of-flight positron emission tomography: status relative to conventional PET. J Nucl Med 24:73–78PubMed

62.

Allemand R, Gresset C, Vacher J (1980) Potential advantages of a cesium fluoride scintillator for a time-of-flight positron camera. J Nucl Med 21:153–155PubMed

63.

Judenhofer MS, Wehrl HF, Newport DF et al (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14:459–465CrossRefPubMed

64.

Pichler BJ, Judenhofer MS, Catana C et al (2006) Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 47:639–647PubMed

65.

Pichler BJ, Judenhofer MS, Wehrl HF (2008) PET/MRI hybrid imaging: devices and initial results. Eur Radiol 18:1077–1086CrossRefPubMed

66.

Boss A, Bisdas S, Kolb A et al (2010) Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 51:1198–1205CrossRefPubMed

67.

Fischer MA, Nanz D, Hany T et al (2010) Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT. Eur Radiol. doi:10.1007/s00330-010-1929-x

68.

Hofmann M, Steinke F, Scheel V et al (2008) MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med 49:1875–1883CrossRefPubMed

69.

Phelps ME (2000) Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 97:9226–9233CrossRefPubMed

Title: Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging
Authors: Christiaan Schiepers
Magnus Dahlbom
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: European Radiology / Issue 3/2011
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-010-2033-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Paediatric cardiac computed tomography: a review of imaging techniques and radiation dose consideration

Tractography of developing white matter of the internal capsule and corpus callosum in very preterm infants

The Holy Grail in diagnostic neuroradiology: 3T or 3D?

Metal-on-metal hip resurfacings—a radiological perspective

Chest computed tomography using iterative reconstruction vs filtered back projection (Part 1): evaluation of image noise reduction in 32 patients

Comparison of diagnostic accuracy and interpretation times for a standard and an advanced 3D visualisation technique in CT colonography